Research Examines Effect of Immunosuppressant on Central Nervous System Disorder

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system similar to multiple sclerosis but even more debilitating.

Bottom Line: In patients with NMOSD, the immunosuppressant medication mycophenolate mofetil (MMF) appears to reduce the frequency of relapse, stabilize or improve disabilities and be well tolerated by patients.

Patients With Central Nervous System Infections may Suffer More
In Vietnam and other locations, patients with central nervous system infections may well be suffering from the effects of a newly discovered virus.

Author: So-Young Huh, M.D., of the University College of Medicine, Busan, Korea, and colleagues.

Background: Disabilities from NMOSD arise due to acute attacks and just one or two attacks can lead to blindness or a walking disability. Preventing the attacks is key to preventing the resulting disabilities. Immunosuppressants such as MMF have been used as therapies to prevent relapse in patients with NMOSD. The authors sought to examine the safety and efficacy of MMF treatment.

How the Study Was Conducted: The authors conducted a three-center review that examined their experiences with 59 patients with NMOSD (24 with neuromyelitis optica and 35 with a limited form of the disease) who were treated with MMF. One of the patients discontinued use of MMF because of a rash so 58 patients were included in the drug-efficacy analysis.

Neuroprotective Effects of Asiaticoside in the Central Nervous System
Asiaticoside has been shown to attenuate in vitro neuronal damage caused by exposure to β-amyloid, in the central nervous system.

Results: The median post-MMF relapse rate was lower than the pre-MMF relapse rate (0.0 vs. 1.5) and disability scores also decreased after MMF treatment (3.0 vs. 2.5). Of the patients, 35 (60 percent) were free of relapse and disability scores stabilized or improved in 53 patients (91 percent). MMF was generally well tolerated.

Discussion: "The next step will be to conduct a randomized clinical trial with long-term efficacy and safety analyses in a larger cohort that can elucidate the efficacy of MMF treatment in patients with NMOSD. "(JAMA Neurol. Published online September 8, 2014. doi:10.1001/.jamaneurol.2014.2057. Available pre-embargo to the media at http://media.jamanetwork.com.)"

The Olig Family Affects Central Nervous System Development in Mammals
The Olig family (oligodendrocyte transcription family) is widely expressed in the central nervous system of various mammals.

Editor's Note: An author made conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Is it Time for a Randomized Trial? In a related editorial, Bruce Cree, M.D., Ph.D, M.A.S., of the University of California, San Francisco, writes: "In this issue, Huh and colleagues report their experience treating 58 patients with NMO [neuromyelitis optica] using MMF. To my knowledge, this is the largest study of MMF treatment in patients with NMO reported thus far."

Central Nervous System Development and Disease Affected by The Olig Family
Research has shown that the oligodendrocyte transcription family (Olig family) is widely expressed in the central nervous system of various mammals.

"Despite the apparent reductions in relapse rates and improvement in disability outcomes, this study has several important limitations that must be recognized before concluding that MMF is an effective treatment for NMO. Most important, there was no parallel control arm," Cree continues.

"Are we ready to conduct clinical trials with MMF or other immune suppressants in treating NMO? Given that various treatments are used empirically to treat NMO, health care professionals and patients need to know whether these empirical therapies are, in fact, effective," Cree notes. (JAMA Neurol. Published online September 8, 2014. doi:10.1001/.jamaneurol.2014.2359. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: The author made a conflict of interest disclosure. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Source-Eurekalert